News and Events

News

All categories

Earnings

Press Release

All years

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

Affimed to Report Second Quarter 2021 Financial Results & Corporate Update on September 8, 2021

August 23, 2021

Affimed Announces Publication of Comprehensive Preclinical Data Demonstrating the Therapeutic Potential of AFM24 in EGFR-expressing Tumors

July 30, 2021

Affimed Reports First Quarter 2021 Financial Results and Highlights Operational Progress

July 1, 2021

Affimed to Report First Quarter 2021 Financial Results & Corporate Update July 1, 2021

June 22, 2021

Affimed Announces Appointment of Uta Kemmerich-Keil to its Supervisory Board

June 16, 2021

Affimed to Present at the Jefferies Virtual Healthcare Conference 2021

May 26, 2021

Affimed Announces Virtual Annual General Meeting of Shareholders

May 20, 2021

Affimed Announces Publication of Preclinical Data in Clinical Cancer Research Supporting Therapeutic Potential of AFM13 in Combination with Natural Killer Cells

May 13, 2021

Affimed Reports 2020 Financial Results and Highlights Recent Operational Progress

April 15, 2021

Affimed Highlights the Potential of its Innate Cell Engager AFM24 as EGFR-targeting Therapy for Solid Tumors as Monotherapy and in Combination with Adoptive NK Cell Transfer at AACR Virtual Annual Meeting I

April 12, 2021

Events

All

Scientific

Investors

02Jun

ASCO Annual Meeting

June 2 - 6, 2023 (Chicago, US)

08Jun

EHA

June 8 - 11, 2023 (Frankfurt, Germany)

13Jun

17-ICML

June 13 - 17, 2023 (Lugano, Switzerland)

Webcasts More events

News and Events

News and Events

See what’s new at Affimed

See what’s new at Affimed

News

Affimed to Report Second Quarter 2021 Financial Results & Corporate Update on September 8, 2021

Affimed Announces Publication of Comprehensive Preclinical Data Demonstrating the Therapeutic Potential of AFM24 in EGFR-expressing Tumors

Affimed Reports First Quarter 2021 Financial Results and Highlights Operational Progress

Affimed to Report First Quarter 2021 Financial Results & Corporate Update July 1, 2021

Affimed Announces Appointment of Uta Kemmerich-Keil to its Supervisory Board

Affimed to Present at the Jefferies Virtual Healthcare Conference 2021

Affimed Announces Virtual Annual General Meeting of Shareholders

Affimed Announces Publication of Preclinical Data in Clinical Cancer Research Supporting Therapeutic Potential of AFM13 in Combination with Natural Killer Cells

Affimed Reports 2020 Financial Results and Highlights Recent Operational Progress

Affimed Highlights the Potential of its Innate Cell Engager AFM24 as EGFR-targeting Therapy for Solid Tumors as Monotherapy and in Combination with Adoptive NK Cell Transfer at AACR Virtual Annual Meeting I

Events

ASCO Annual Meeting

EHA

17-ICML